ArticleFrontiers in medicine2026

Venetoclax plus azacitidine in higher-risk myelodysplastic syndromes: a treatment-purpose framework for interpreting response depth.

Xinfu Zou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.